Can chronic gastritis cause an increase in fecal calprotectin concentrations?

被引:0
|
作者
Massimo Montalto [1 ]
Antonella Gallo [1 ]
Gianluca Ianiro [1 ]
Luca Santoro [1 ]
Ferruccio D'Onofrio [1 ]
Riccardo Ricci [2 ]
Giovanni Cammarota [1 ]
Marcello Covino [1 ]
Monica Vastola [1 ]
Antonio Gasbarrini [1 ]
Giovanni Gasbarrini [1 ]
机构
[1] Institute of Internal Medicine,Catholic University
[2] Institute of Pathology,Catholic University
关键词
Chronic gastritis; Fecal calprotectin; Intestinal inflammation; Neutrophils;
D O I
暂无
中图分类号
R573.3 [胃炎];
学科分类号
1002 ; 100201 ;
摘要
AIM:To evaluate fecal calprotectin concentrations(FCCs) in subjects with chronic gastritis and the correlation between FCCs and gastritis activity score.METHODS:FCCs were measured in 61 patients with histological diagnosis of gastritis and in 74 healthy volunteers.Histological grading of gastritis was performed according to the updated Sydney gastritis classification.Patients were subdivided into 2 groups according to the presence/absence of an active gastritis.Patients with chronic active gastritis were divided into 3 subgroups on the basis of the activity score(mild,moderate,marked).FFCs in relation to Helicobacter pylori(H.pylori) infection and proton pump inhibitor(PPI) use were also evaluated.RESULTS:FCCs in patients with chronic active gastritis were not significantly different to FCCs either in subjects with non active gastritis or in healthy controls.Among patients with chronic active gastritis(even marked),FCCs did not significantly differ according to activity score.No significant differences in FCCs were found when considering H.pylori,as well as when considering PPI chronic use.CONCLUSION:FCCs were not significantly increased in subjects with chronic gastritis,even in those patients with a marked neutrophil infiltration.
引用
收藏
页码:3406 / 3410
页数:5
相关论文
共 33 条
  • [21] Can 2 Different Fecal Calprotectin Assays be Used Interchangeably in IBD Treatment?
    van Wassenaer, Elsa A.
    Diederen, Kay
    van Leeuwen, Ester M. M.
    D'Haens, Geert R.
    Benninga, Marc A.
    Koot, Bart G. P.
    Kindermann, Angelika
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2022, 56 (01) : E27 - E30
  • [22] Can fecal calprotectin levels be used to monitor infant milk protein allergies?
    Liyan Qiu
    Junli Wang
    Fang Ren
    Lixiao Shen
    Feng Li
    Allergy, Asthma & Clinical Immunology, 17
  • [23] Influence of Breed Size, Age, Fecal Quality, and Enteropathogen Shedding on Fecal Calprotectin and Immunoglobulin A Concentrations in Puppies During the Weaning Period
    Grellet, A.
    Heilmann, R. M.
    Polack, B.
    Feugier, A.
    Boucraut-Baralon, C.
    Grandjean, D.
    Grutzner, N.
    Suchodolski, J. S.
    Steiner, J. M.
    Chastant-Maillard, S.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2016, 30 (04) : 1056 - 1064
  • [24] Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
    Sandborn, William J.
    Panes, Julian
    Zhang, Haiying
    Yu, Dahong
    Niezychowski, Wojciech
    Su, Chinyu
    GASTROENTEROLOGY, 2016, 150 (01) : 96 - 102
  • [25] Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? - A Pilot Study
    Koszewicz, Magdalena
    Mulak, Agata
    Dziadkowiak, Edyta
    Budrewicz, Slawomir
    FRONTIERS IN HUMAN NEUROSCIENCE, 2021, 15
  • [26] Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?
    Dincer, Busra Tetik
    Usta, Ayse Merve
    Kural, Alev
    Helvaci, Nazli
    Ucar, Ahmet
    Urganci, Nafiye
    BMC PEDIATRICS, 2024, 24 (01)
  • [27] Evaluating the Efficacy of Fecal Immunochemical Test, Fecal Calprotectin, and Serum C-Reactive Protein in Diagnosing Patients With Chronic Lower Gastrointestinal Symptoms
    Limsrivilai, Julajak
    Yodmalai, Chatrawee
    Chaemsupaphan, Thanaboon
    Sattayalertyanyong, Onuma
    Subdee, Nichcha
    Permpim, Parinya
    Phaophu, Phutthaphorn
    Kaosombatwattana, Uayporn
    Pausawasdi, Nonthalee
    Riansuwan, Woramin
    Charatcharoenwitthaya, Phunchai
    Pongprasobchai, Supot
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (08)
  • [28] Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease
    Fernandes, Samuel Raimundo
    Bernardo, Sonia
    Saraiva, Sofia
    Goncalves, Ana Rita
    Moura Santos, Paula
    Valente, Ana
    Correia, Luis Araujo
    Cortez-Pinto, Helena
    Magro, Fernando
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (04) : 451 - 458
  • [29] Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease
    Koller, Tomas
    Vrbova, Petra
    Kubanek, Natalia
    Zilincanova, Daniela
    Selcanova, Svetlana Adamcova
    Havaj, Daniel Jan
    Skladany, Lubomir
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, : 305 - 316
  • [30] Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?
    Dilaghi, Emanuele
    Carabotti, Marilia
    Annibale, Bruno
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (09) : 1107 - 1110